Sector

Nifty at record highs – Time to stay put or take the gains?

India is a fundamentally strong long-term growth story. Therefore, every opportunity should be used to buy on decline and not sell on rally

Unified tariffs will aid gas buyers, benefits uncertain for companies

The Petroleum and Natural Gas Regulatory Board plans to implement unified tariff regulations for natural gas infrastructure from April 1, 2023

Why green energy stocks fail to click with investors

Inox Green Energy Services dropped below its IPO price on its listing debut. Others such as ReNew Energy and Sterling and Wilson too have delivered a disappointing performance since listing

For IEX investors, a buyback may provide limited relief

Increased competition in the core electricity trading business is leading analysts to fear it may cede market share to new entrants

Steel sector – Export duty cut a welcome step but with limited benefits

Experts suggest it would not be correct to state that the imposition of export duty was the only key reason for correction in domestic steel prices. It should be noted that prices were already in correction mode when the export duty was imposed.

Aarti Industries: Post demerger, a pure play on aromatic chemistry

The near-term growth profile is blurred by a potential decline in realisations and the persistence of demand weakness

Safari – What after the huge outperformance?

The consistent financial performance and strong sector tailwinds make Safari a very interesting bet for the long term

Dhanuka Agritech: Buyback doesn’t make us a buyer of this stock

Margin pressure remains extended, near-term growth triggers remain limited

What can help Mrs Bectors reduce its valuation gap with Britannia

Mrs Bectors’ revenue increased 37 percent in H1 FY23, faster than the 16 percent rise at Britannia

Q2 results show Indian healthcare sector firmly on recovery path

Healthcare companies expect the growth momentum to continue, driven by the addition of new hospital beds, services and optimisation of existing facilities

Galaxy Surfactants: H2 expected to be weaker than H1FY23

Galaxy Surfactants has improved in the global logistics situation and a drop in raw material prices. In the backdrop of a muted volume growth outlook, we believe investors need to be guarded

PI Industries: Standing strong in testing times

PI’s superior execution with a solid business model accompanied with surplus cash and backward integration strategies makes it a perfect stock to be bought on declines

Divi’s and Gland Pharma’s weak results show B2B model not without risks

Post the weak September quarter results, analysts fear revenue may decline at both the companies in FY23

Coromandel International: There is a long-term value case for this stock

We resume coverage on Coromandel, with a recommendation to accumulate the stock for long-term gains

Archean Chemical: Company plans to clean balance sheet through IPO

Archean Chemical had a checkered history in terms of debt management and struggled to execute its expansion plan one time. A successful IPO, however, can provide a clean slate this time to foray into bromine derivatives

Growth drivers are finally falling in place for large pharma companies

Analysts project a notable improvement in revenue growth rates at Sun Pharma, Dr Reddy’s Labs, Cipla vis-à-vis FY17-22

When will rural FMCG demand recover? The answer lies in purchasing power

While higher farm prices can improve farm income, the real impetus for rural demand recovery can only come if wages grow ahead of inflation

Cognizant's guidance cut holds a cautionary message for Indian IT

IT companies should think twice before scaling down their employee base as rebuilding capacity can be difficult

Mas Financial Q2 FY23: Stellar run; is the rerating over?

While tactically it makes sense to book gains in Mas Financial after such a sharp run-up, investors should look to add the stock on declines for the long term

Global Health IPO: Play on regional healthcare demand, subscribe for long term

A rebound in patient visits and elective procedures have contributed to the improving economics for hospital chains. Medanta is play on this demand, particularly in the north and east of India

Tech Mahindra Q2 – Can the margin beat be the reason to buy the stock?

The IT company lags larger peers in growth as well as margin. A few more quarters of soft performance is not ruled out, given the challenging macro scenario

Sumitomo Chemical India: Look beyond the glyphosate usage notification

Overall, SCIL has a strong growth potential owing to the healthy launches in the domestic market

Control Print: What the soft patch means for investors

The medium-term prospects for Control Print look good as multiple levers will fuel its growth

UPL’s stake sales may yield limited gains in the near term

Analysts largely left earnings estimates unchanged as debt is expected to see limited reduction